Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study

Kenneth G. Saag, Rachel B. Wagman, Piet Geusens, Jonathan D. Adachi, Osvaldo D. Messina, Ronald Emkey, Roland Chapurlat, Andrea Wang, Nicola Pannacciulli, Willem F. Lems

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)445-454
Number of pages10
JournalThe Lancet Diabetes & Endocrinology
Volume6
Issue number6
DOIs
Publication statusPublished - 1 Jun 2018

Keywords

  • CORTICOSTEROID-INDUCED OSTEOPOROSIS
  • INDUCED BONE LOSS
  • POSTMENOPAUSAL WOMEN
  • CONTROLLED-TRIAL
  • UNITED-STATES
  • PREVENTION
  • MANAGEMENT
  • FRACTURE
  • THERAPY
  • ALENDRONATE
  • INHIBITION
  • PREVALENCE

Cite this